Document is current
Any future updates will be listed below
-
Authors
Nishikubo, Megumi https://orcid.org/0000-0001-7618-1379
Tanaka, Yugo
Mitsui, Suguru
Doi, Takefumi https://orcid.org/0000-0003-1092-0700
Hokka, Daisuke
Hojo, Wataru
Sakai, Hironori
Funakoshi, Yohei
Yakushijin, Kimikazu
Ohji, Goh https://orcid.org/0000-0002-9947-020X
Minami, Hironobu
Maniwa, Yoshimasa
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000047380 at UMIN JapanDocuments that mention this clinical trial
Comparable efficacy and safety of COVID-19 vaccines for patients receiving tegafur–uracil as postoperative adjuvant chemotherapy
https://doi.org/10.1007/s00595-023-02649-1
-
Funding
Funding for this research was provided by:
Kobe University
- License Information
-
More Information
Article History
Received: 1 June 2022
Accepted: 5 January 2023
First Online: 8 February 2023
Declarations
:
: Yugo Tanaka received a lecture fee from Johnson & Johnson K.K.; Wataru Hojo and Hironori Sakai are employed by Cellspect Co., Ltd.; QuaResearch COVID‐19 Human IgM IgG ELISA Kit was provided by R&D, Cellspect Co., Ltd.; Hironobu Minami received research funding from Pfizer and a scholarship donation from Pfizer and Taiho Pharma. The other authors have no conflicts of interest.
: The protocol was implemented in accordance with the principles of the Declaration of Helsinki with approval from the Clinical Research Area Ethics Committee of Kobe University Graduate School of Medicine (B2156703 approved July 16, 2021). All patients provided written informed consent before inclusion in this study.
